var data={"title":"Rotigotine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Rotigotine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/243711?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=rotigotine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Rotigotine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14699479\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Neupro</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23905578\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Neupro</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4801855\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anti-Parkinson Agent, Dopamine Agonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4801889\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Parkinson disease:</b> Topical: Transdermal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Early-stage:</i> Initial: Apply 2 mg/24 hours patch once daily; may increase by 2 mg/24 hours weekly, based on clinical response and tolerability; lowest effective dose: 4 mg/24 hours (manufacturer recommends a maximum dose of 6 mg/24 hours; higher doses [eg, 8 mg/24 hours] have been studied in clinical trials [Giladi 2007]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Advanced-stage:</i> Initial: Apply 4 mg/24 hours patch once daily; may increase by 2 mg/24 hours weekly, based on clinical response and tolerability. Recommended dose: 8 mg/24 hours; in clinical trials maximum doses up to 16 mg/24 hours were used.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Discontinuation of treatment in Parkinson disease:</i> Decrease by &le;2 mg/24 hours preferably every other day until withdrawal complete</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Restless legs syndrome (RLS):</b> Topical: Transdermal: Initial: Apply 1 mg/24 hours patch once daily; may increase by 1 mg/24 hours weekly, based on clinical response and tolerability; lowest effective dose: 1 mg/24 hours (maximum dose: 3 mg/24 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Discontinuation of treatment for RLS:</i> Decrease by 1 mg/24 hours preferably every other day until withdrawal complete</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4801890\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4801891\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild-to-severe impairment (CrCl &ge;15 mL/minute): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">End-stage renal disease (ESRD) requiring hemodialysis: No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4801892\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Mild-to-moderate hepatic impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Severe hepatic impairment: There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14699480\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Patch 24 Hour, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neupro: 1 mg/24 hr (30 ea); 2 mg/24 hr (30 ea); 3 mg/24 hr (30 ea); 4 mg/24 hr (30 ea); 6 mg/24 hr (30 ea); 8 mg/24 hr (30 ea) [contains sodium metabisulfite]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4801854\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4801893\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Transdermal patch: Apply patch to clean, dry, hairless area of intact healthy skin on the front of the abdomen, thigh, hip, flank, shoulder, or upper arm at approximately the same time daily. Remove from pouch immediately before use and press patch firmly in place on skin for 30 seconds. Application sites should be rotated on a daily basis. Do not apply to same application site more than once every 14 days or apply patch to oily, irritated or damaged skin. Avoid exposing patch to external heat sources (eg, heating pad, electric blanket, heat lamp, hot tub, direct sunlight). If applied to hairy area, shave &ge;3 days prior to applying patch. If patch falls off, immediately apply a new one to a new site.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3335289\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Parkinson disease:</b> For the treatment of Parkinson disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Restless legs syndrome:</b> For the treatment of moderate to severe primary restless legs syndrome.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4801851\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Sound-alike/look-alike issues: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neupro may be confused with Neupogen</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">Transdermal patch contains metal (eg, aluminum); remove patch prior to MRI or cardioversion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4801865\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Systolic hypotension (13% to 32%), peripheral edema (dose related; 3% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Drowsiness (dose related; 5% to 32%), orthostatic hypotension (8% to 29%), dizziness (5% to 23%), headache (10% to 21%), fatigue (6% to 18%), sleep disorder (disturbance in initiating/maintaining sleep; dose related; 2% to 14%), malaise (&le;14%), hallucination (dose related; 3% to 13%), insomnia (7% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Hyperhidrosis (dose related; 1% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Decreased serum glucose (1% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (dose related; 15% to 48%), vomiting (dose related; 2% to 20%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Decreased hematocrit (8% to 17%), decreased hemoglobin (8% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Application site reaction (dose related; 21% to 46%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Dyskinesia (dose related; 14% to 17%), weakness (&le;14%), arthralgia (8% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Increased diastolic blood pressure (4% to 8%), systolic hypertension (5%), hypertension (dose related; 1% to 5%), atrioventricular block (3%), abnormal T waves on ECG (&le;3%), syncope </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Abnormal dreams (dose related; 1% to 7%), nightmares (dose related; 3% to 5%), depression (2% to 5%), paresthesia (dose related; 4%), vertigo (3% to 4%), equilibrium disturbance (2% to 3%), irritability (1% to 3%), narcolepsy (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (4% to 9%), erythema (dose related; 2% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight gain (2% to 9%), change in libido (4% to 6%), hot flash (3% to 4%), low serum ferritin (dose related; 2%), menstrual disorder (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation (5% to 9%), anorexia (2% to 9%), xerostomia (dose related; 7%), diarrhea (5% to 7%), dyspepsia (dose related; 2% to 3%), viral gastroenteritis (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Change in WBC count (urine, &le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Basal cell carcinoma (3%), leukocyturia (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Herpes simplex infection (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Tremor (4%), muscle spasm (dose related; 3% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Visual disturbance (3% to 5%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Tinnitus (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased blood urea nitrogen (3% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (8% to 10%), cough (3%), nasal congestion (3%), sinus congestion (2% to 3%), sinusitis (dose related; 2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Hiccups (dose related; 2% to 3%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Agitation, aggressive behavior, confusion, delirium, delusions, disorientation, impulse control disorder, increased creatine phosphokinase, neuroleptic malignant syndrome (resembling), paranoia, psychotic symptoms, skin rash</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4801861\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to rotigotine or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4801862\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Application site reactions: Dose-dependent application site reactions, potentially severe, have been observed; daily rotation of application sites has been shown to decrease incidence of reactions. If a generalized (nonapplication site) skin reaction occurs; discontinue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fibrosis: Rare cases of pleural effusion, pleural thickening, pulmonary infiltrates, retroperitoneal fibrosis, pericarditis and/or cardiac valvulopathy have been reported in patients treated with ergot-derived dopamine agonists. The potential of rotigotine, a nonergot derived dopamine agonist, to cause similar fibrotic complications is unknown. Discontinuation of therapy may resolve complications, but not in all cases.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid retention: Weight gain and fluid retention have been reported, primarily associated with development of peripheral edema in Parkinson disease patients; use caution and monitor for weight gain in patients with concomitant illnesses (eg, heart failure or renal insufficiency).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hallucinations/psychotic-like behavior: May cause hallucinations (dose-related) and other psychotic-like behaviors (eg, agitation, delirium, delusions, aggression). In general, avoid use in patients with preexisting major psychotic disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Impulse control disorders: Dopamine agonists used for Parkinson disease or restless legs syndrome have been associated with compulsive behaviors and/or loss of impulse control, which has manifested as pathological gambling, libido increases (hypersexuality), and/or binge eating. Causality has not been established, and controversy exists as to whether this phenomenon is related to the underlying disease, prior behaviors/addictions and/or drug therapy. Dose reduction or discontinuation of therapy has been reported to reverse these behaviors in some, but not all cases.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Melanoma: Risk for melanoma development is increased in Parkinson disease patients; drug causation or factors contributing to risk have not been established. Patients receiving therapy for any indication should be monitored closely and periodic skin examinations should be performed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Orthostatic hypotension: Dopamine agonists may cause orthostatic hypotension and syncope; Parkinson disease patients appear to have an impaired capacity to respond to a postural challenge. Use with caution in patients at risk of hypotension (such as those receiving antihypertensive drugs) or where transient hypotensive episodes would be poorly tolerated (cardiovascular disease or cerebrovascular disease). Parkinson and RLS patients being treated with dopaminergic agonists ordinarily require careful monitoring for signs and symptoms of postural hypotension, especially during dose escalation, and should be informed of this risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Somnolence: Use is commonly associated with somnolence. In addition, falling asleep during activities of daily living, including while driving, has also been reported and may occur without significant warning signs. Monitor for daytime somnolence or pre-existing sleep disorder. Patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Use with caution in patients receiving other CNS depressants or psychoactive agents; discontinue if significant daytime sleepiness or episodes of falling asleep occur. Effects with other sedative drugs or ethanol may be potentiated.</p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">\n      <b>\n        <i>Disease-related concerns: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with pre-existing cardiovascular disease; therapy has been associated with increases in blood pressure (as well as orthostatic hypotension), which may be significant (&gt;40 mm Hg or &ge;20 mm Hg increase in systolic or diastolic measurements, respectively), increased heart rate, syncope, and weight gain/fluid retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dyskinesia: Use with caution in patients with preexisting dyskinesia; therapy may cause or exacerbate dyskinesia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Restless legs syndrome: Augmentation (earlier onset of symptoms each day and/or an overall increase in symptom severity) may occur in some restless leg syndrome (RLS) patients. Risk factors for dopaminergic-induced augmentation include higher doses of dopaminergic agents, use of shorter-acting dopamine agonists (ie, pramipexole, ropinirole) or levodopa, low iron stores, and increased severity of symptoms prior to treatment initiation. To minimize risk of augmentation, use the lowest effective dose and avoid exceeding recommended doses. Patients may also be switched to alternative therapy if augmentation occurs (Garcia-Borreguero 2016). End-of-dose rebound (reappearance of symptoms in the early morning hours) may also occur. Consider dosage adjustment or discontinuation of treatment if rebound symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aluminum: Patch contains aluminum; remove patch prior to magnetic resonance imaging or cardioversion to avoid skin burns.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heat application: Avoid exposure of application site to any direct external heat sources (eg, hair dryers, heating pads, electric blankets, saunas, hot tubs, direct sunlight); heat exposure has not been studied with the rotigotine patch, but an increase in the rate and extent of absorption has been observed with other transdermal products.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sulfites: Patch contains sodium metabisulfite which may cause allergic reaction in susceptible individuals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: Taper treatment when discontinuing therapy; do not stop abruptly. Other dopaminergic agents have been associated with a syndrome resembling neuroleptic malignant syndrome on withdrawal and/or significant dosage reduction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14192539\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4801872\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=83322&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the sedative effect of Rotigotine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amisulpride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Amisulpride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (First Generation [Typical]): May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Antipsychotic Agents (First Generation [Typical]). Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: Anti-Parkinson Agents (Dopamine Agonist) may enhance the adverse/toxic effect of BuPROPion. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the sedative effect of Rotigotine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the adverse/toxic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulpiride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4801856\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4801857\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4801860\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if rotigotine is excreted in breast milk. Rotigotine decreases prolactin secretion and lactation may be inhibited. The manufacturer recommends that caution be exercised when administering rotigotine to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4801895\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure (including orthostatic); daytime alertness; periodic skin evaluations (melanoma development)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4801878\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Rotigotine is a nonergot dopamine agonist with specificity for D<sub>3</sub>-, D<sub>2</sub>-, and D<sub>1</sub>-dopamine receptors. Although the precise mechanism of action of rotigotine is unknown, it is believed to be due to stimulation of postsynaptic dopamine D<sub>2</sub>-type auto receptors within the substantia nigra in the brain, leading to improved dopaminergic transmission in the motor areas of the basal ganglia, notably the caudate nucleus/putamen regions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4801880\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: ~84 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensive via conjugation and N-dealkylation; multiple CYP isoenzymes, sulfotransferases, and two UDP-glucuronosyltransferases involved in catalyzing the metabolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: After removal of patch: ~5 to 7 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: 15 to 18 hours; can occur 4 to 27 hours post application</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~71% as inactive conjugates and metabolites, &lt;1% as unchanged drug); feces (~23%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570474\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, 24-hour</b> (Neupro Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/24 hrs (30): $775.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/24 hrs (30): $775.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg/24 hrs (30): $775.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/24 hrs (30): $775.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg/24 hrs (30): $775.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg/24 hrs (30): $775.94</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4302646\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Leganto (IE, MT);</li>\n      <li>Neupro (AE, AR, AT, AU, BB, BE, BH, BM, BR, CH, CL, CY, CZ, DE, DK, EE, ES, FR, GB, GR, HK, HR, HU, ID, IE, IL, IT, JP, KR, KW, LB, LT, LU, MT, MY, NL, NO, PH, PL, PT, RO, SE, SG, SI, SK, TH, TR, TW, UA, VN);</li>\n      <li>Nubrenza (CR, DO, GT, HN, NI, PA, SV)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Factor SA, &ldquo;Current Status of Symptomatic Medical Therapy in Parkinson's Disease,&rdquo; <i>Neurotherapeutics</i>, 2008, 5(2):164-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rotigotine-drug-information/abstract-text/18394561/pubmed\" target=\"_blank\" id=\"18394561\">18394561</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. <i>Sleep Med</i>. 2016;21:1-11. doi: 10.1016/j.sleep.2016.01.017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rotigotine-drug-information/abstract-text/27448465/pubmed\" target=\"_blank\" id=\"27448465\">27448465</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giladi N, Boroojerdi B, Korczyn AD, et al. Rotigotine transdermal patch in early Parkinson's Disease: a randomized, double-blind, controlled study versus placebo and ropinirole. <i>Mov Disord</i>. 2007;22(16):2398-2404.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rotigotine-drug-information/abstract-text/17935234/pubmed\" target=\"_blank\" id=\"17935234\">17935234</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Molina JA, S&agrave;inz-Artiga MJ, Fraile A, et al, &ldquo;Pathologic Gambling in Parkinson's Disease: A Behavioral Manifestation of Pharmacologic Treatment,&rdquo; <i>Mov Disord</i>, 2000, 15(5):869-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rotigotine-drug-information/abstract-text/11009192/pubmed\" target=\"_blank\" id=\"11009192\">11009192</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neupro (rotigotine) [US prescribing information]. Smyrna, GA: UCB Inc; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reichmann H, Bilsing A, Ehret R, et al, &ldquo;Ergoline and Non-Ergoline Derivatives in the Treatment of Parkinson's Disease,&rdquo; <i>J Neurol</i>, 2006, 253(Suppl 4):36-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rotigotine-drug-information/abstract-text/16944356/pubmed\" target=\"_blank\" id=\"16944356\">16944356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reynolds NA, Wellington K, and Easthope SE, &ldquo;Rotigotine in Parkinson's Disease,&rdquo; <i>CNS Drugs</i>, 2005, 19(11):973-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rotigotine-drug-information/abstract-text/16268667/pubmed\" target=\"_blank\" id=\"16268667\">16268667</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weintraub D, Siderowf AD, Potenza MN, et al, &ldquo;Association of Dopamine Agonist Use With Impulse Control Disorders in Parkinson Disease,&rdquo; <i>Arch Neurol</i>, 2006, 63(7):969-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rotigotine-drug-information/abstract-text/16831966/pubmed\" target=\"_blank\" id=\"16831966\">16831966</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 83322 Version 94.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F14699479\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F23905578\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F4801855\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F4801889\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F4801890\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F4801891\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F4801892\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F14699480\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F4801854\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F4801893\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F3335289\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F4801851\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F4801865\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F4801861\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F4801862\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F14192539\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F4801872\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F4801856\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F4801857\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F4801860\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F4801895\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F4801878\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F4801880\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16570474\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F4302646\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/83322|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=rotigotine-patient-drug-information\" class=\"drug drug_patient\">Rotigotine: Patient drug information</a></li></ul></div></div>","javascript":null}